drugset / Trial / NCT02327936

Fesoterodine and Oxybutynin XL for Overactive Bladder Syndrome in Children

NCT02327936

Phase 3 Completed 62 enrolled Stéphane Bolduc Pfizer · collab
RandomizedCrossoverSingle-blindTreatment

Summary

The purpose of this study is to evaluate the tolerability of Fesoterodine and Oxytbutynin XL and to compare their efficacy for overactive bladder syndrome in children.

Timeline

Start
2014-12
Primary completion
2018-03
Completion
2018-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Fesoterodine Other / unclassified 4 mg Oral
Subject Fesoterodine Other / unclassified 8 mg Oral
Comparator Oxybutynin XL Unknown 10 mg Oral
Comparator Oxybutynin XL Unknown 20 mg Oral

Indications